FTFrancesca Tarantini

Francesca Tarantini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Francesca Tarantini has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Claudia Di Serio

    Geriatric Medicine Unit, Department of Critical Care Medicine and Surgery, University of Florence (Italy)

    5 shared publications
  • Igor Prudovsky

    Maine Medical Center Research Institute (MMCRI), Scarborough, ME (USA)

    4 shared publications
  • Niccolò Marchionni

    Geriatric Medicine Unit, Department of Critical Care Medicine and Surgery, University of Florence (Italy)

    4 shared publications
  • Annamaria Piscazzi

    Clinical Oncology Unit, Department of Medical Sciences, University of Foggia (Italy)

    2 shared publications
  • Daniela Massi

    Division of Pathological Anatomy, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy

    2 shared publications
  • Fabiana Rosati

    Endocrine Unit, Department of Clinical Physiopathology, University of Florence (Italy)

    2 shared publications

Latest Publications

  • Open Access

    Notch3 is activated by chronic hypoxia and contributes to the progression of human prostate cancer

    by Giovanna Danza, Claudia Di Serio, Maria Raffaella Ambrosio, Niccolò Sturli, Giuseppe Lonetto, Fabiana Rosati, Bruno Jim Rocca, Giuseppina Ventimiglia, Maria Teresa del Vecchio, Igor Prudovsky, et al.

    Prostate cancer (PC) is still the second cause of cancer‐related death among men. Although patients with metastatic presentation have an ominous outcome, the vast majority of PCs are diagnosed at an early stage. Nonetheless, even among patients with clinically localized disease the outcome may vary considerably. Other than androgen sensitivity, little is known about which other signaling pathways are deranged in aggressive, localized cancers. The elucidation of such pathways may help to develop innovative therapies aimed at specific molecular targets. We report that in a hormone‐sensitive PC cell line, LNCaP, Notch3 was activated by hypoxia and sustained cell proliferation and colony formation in soft agar. Hypoxia also modulated cellular cholesterol content and the number and size of lipid rafts, causing a coalescence of small rafts into bigger clusters; under this experimental condition, Notch3 migrated from the non‐raft into the raft compartment where it colocalized with the γ‐secretase complex. We also looked at human PC biopsies and found that expression of Notch3 positively correlated with Gleason score and with expression of carbonic anhydrase IX, a marker of hypoxia. In conclusion, hypoxia triggers the activation of Notch3, which, in turn, sustains proliferation of PC cells. Notch3 pathway represents a promising target for adjuvant therapy in patients with PC.


  • Open Access

    Notch Signaling Modulates Hypoxia-Induced Neuroendocrine Differentiation of Human Prostate Cancer Cells

    by Giovanna Danza, Claudia Di Serio, Fabiana Rosati, Giuseppe Lonetto, Niccolò Sturli, Doreen Kacer, Antonio Pennella, Giuseppina Ventimiglia, Riccardo Barucci, Annamaria Piscazzi, et al.

    Prostate carcinoma is among the most common causes of cancer-related death in men, representing 15% of all male malignancies in developed countries. Neuroendocrine differentiation (NED) has been associated with tumor progression, poor prognosis, and with the androgen-independent status. Currently, no successful therapy exists for advanced, castration-resistant disease. Because hypoxia has been linked to prostate cancer progression and unfavorable outcome, we sought to determine whether hypoxia would impact the degree of neuroendocrine differentiation of prostate cancer cells in vitro. Results: Exposure of LNCaP cells to low oxygen tension induced a neuroendocrine phenotype, associated with an increased expression of the transcription factor neurogenin3 and neuroendocrine markers, such as neuron-specific enolase, chromogranin A, and β3-tubulin. Moreover, hypoxia triggered a significant decrease of Notch 1 and Notch 2 mRNA and protein expression, with subsequent downregulation of Notch-mediated signaling, as shown by reduced levels of the Notch target genes, Hes1 and Hey1. NED was promoted by attenuation of Hes1 transcription, as cells expressing a dominant-negative form of Hes1 displayed increased levels of neuroendocrine markers under normoxic conditions. Although hypoxia downregulated Notch 1 and Notch 2 mRNA transcription and receptor activation also in the androgen-independent cell lines, PC-3 and Du145, it did not change the extent of NED in these cultures, suggesting that androgen sensitivity may be required for transdifferentiation to occur. Conclusions: Hypoxia induces NED of LNCaP cells in vitro, which seems to be driven by the inhibition of Notch signaling with subsequent downregulation of Hes1 transcription. Mol Cancer Res; 10(2); 230–8. ©2011 AACR.


  • Open Access

    Adiponectin, diabetes and ischemic heart failure: a challenging relationship

    by Samuele Baldasseroni, Alessandro Antenore, Claudia Di Serio, Francesco Orso, Giuseppe Lonetto, Nadia Bartoli, Alice Foschini, Andrea Marella, Alessandra Pratesi, Salvatore Scarantino, et al.

    Several peptides, named adipokines, are produced by the adipose tissue. Among those, adiponectin (AD) is the most abundant. AD promotes peripheral insulin sensitivity, inhibits liver gluconeogenesis and displays anti-atherogenic and anti-inflammatory properties. Lower levels of AD are related to a higher risk of myocardial infarction and a worse prognosis in patients with coronary artery disease. However, despite a favorable clinical profile, AD increases in relation to worsening heart failure (HF); in this context, higher adiponectinemia is reliably related to poor prognosis. There is still little knowledge about how certain metabolic conditions, such as diabetes mellitus, modulate the relationship between AD and HF. We evaluated the level of adiponectin in patients with ischemic HF, with and without type 2 diabetes, to elucidate whether the metabolic syndrome was able to influence the relationship between AD and HF. We demonstrated that AD rises in patients with advanced HF, but to a lesser extent in diabetics than in non-diabetics. Diabetic patients with reduced systolic performance orchestrated a slower rise of AD which began only in face of overt HF. The different behavior of AD in the presence of diabetes was not entirely explained by differences in body mass index. In addition, NT-proBNP, the second strongest predictor of AD, did not differ significantly between diabetic and non-diabetic patients. These data indicate that some other mechanisms are involved in the regulation of AD in patients with type 2 diabetes and coronary artery disease. AD rises across chronic heart failure stages but this phenomenon is less evident in type 2 diabetic patients. In the presence of diabetes, the progressive increase of AD in relation to the severity of LV dysfunction is hampered and becomes evident only in overt HF.


  • S100A13 is a new angiogenic marker in human melanoma

    by Daniela Massi, Matteo Landriscina, Annamaria Piscazzi, Elena Cosci, Alek Kirov, Milena Paglierani, Claudia Di Serio, Vasileios Mourmouras, Stefano Fumagalli, Maurizio Biagioli, et al.


  • Severe hyponatremia due to hypopituitarism with adrenal insufficiency: A case report

    by F. Tarantini, S. Fumagalli, L. Boncinelli, M. C. Cavallini, E. Mossello, N. Marchionni

    Objective: Adrenal insufficiency due to hypopituitarism can lead to severe hyponatremia with potentially fatal consequences. Prompt diagnosis and adequate hormonal replacement therapy are essential to block an otherwise unfavorable course and to re-establish a healthy life. Unfortunately, this condition is often misdiagnosed. Design: Case report. Setting: Intensive Care Unit of a teaching hospital. Patient: A 76-yr-old man with refractory hypotension, acute myocardial infarction, and left ventricular dysfunction, secondary to severe chronic pan-hypopituitarism, associated with severe hyponatremia. Methods and main results: The patient underwent mechanical ventilation and continuous venous-venous hemodiafiltration, for severe respiratory and renal insufficiency. A hormonal replacement therapy with T4, hydrocortisone, and nandrolone was started and the patient was discharged to a rehabilitation facility after 31 days of hospitalization. Conclusions: Hypopituitarism with secondary adrenal insufficiency is often misdiagnosed at an early stage and a high degree of suspicion is necessary for early diagnosis. Determination of plasma cortisol level in patients with hyponatremia not explained by other causes should always be obtained.


  • Protease‐Activated Receptor 1‐Selective Antagonist SCH79797 Inhibits Cell Proliferation and Induces Apoptosis by a Protease‐Activated Receptor 1‐Independent Mechanism

    by Claudia Di Serio, Silvia Pellerito, Maria Duarte, Daniela Massi, Antonella Naldini, Giuseppe Cirino, Igor Prudovsky, Marco Santucci, Pierangelo Geppetti, Niccolò Marchionni, et al.

    Abstract:  Thrombin, a key mediator of blood coagulation, exerts a large number of cellular actions via activation of a specific G‐protein‐coupled receptor, named protease‐activated receptor 1 (PAR1). Several studies in experimental animals have demonstrated a therapeutic potential of small molecules with PAR1 antagonistic properties for treatment of diseases such as vascular thrombosis and arterial restenosis. We have studied the biological actions of one highly potent, selective PAR1 antagonist, SCH79797 (N3‐cyclopropyl‐7‐{[4‐(1‐methylethyl)phenyl]methyl}‐7H‐pyrrolo[3,2‐f]quinazoline‐1,3‐diamine),in vitro, and found that this compound was able to interfere with the growth of several human and mouse cell lines, in a concentration‐dependent manner. The ED50for growth inhibition was 75 nM, 81 nM and 116 nM for NIH 3T3, HEK 293 and A375 cells, respectively. Moreover, in NIH 3T3 cells, SCH79797 inhibited serum‐stimulated activation of p44/p42 mitogen‐activated protein kinases (MAPK) at low concentrations and induced apoptosis at higher concentrations. However, the antiproliferative and pro‐apoptotic effects of SCH79797 are likely not mediated by PAR1 antagonism, as they were also observed in embryonic fibroblasts derived from PAR1 null mice. These data suggest that, in view of the development of PAR1‐selective antagonists as therapeutic agents, effects potentially unrelated to PAR1 inhibition should be carefully scrutinized.


  • Kynurenic Acid Inhibits the Release of the Neurotrophic Fibroblast Growth Factor (FGF)-1 and Enhances Proliferation of Glia Cells, in vitro

    by Claudia Di Serio, Andrea Cozzi, Ilaria Angeli, Laura Doria, Isabella Micucci, Silvia Pellerito, Patrizia Mirone, Giulio Masotti, Flavio Moroni, Francesca Tarantini

    Kynurenic (KYNA) and quinolinic (QUIN) acids are neuroactive tryptophan metabolites formed along the kynurenine pathway: the first is considered a non-competitive antagonist and the second an agonist of glutamate receptors of NMDA type. The affinity of these compounds for glutamate receptors is, however, relatively low and does not explain KYNA neuroprotective actions in models of post-ischemic brain damage. We evaluated KYNA effects on the release of fibroblast growth factor (FGF)-1, a potent neurotrophic cytokine. Because KYNA exhibits a neuroprotective profile in vitro and in vivo, we anticipated that it could function as an autocrine/paracrine inducer of FGF-1 release. Studies were performed in several models of FGF-1 secretion (FGF-1 transfected NIH 3T3 cells exposed to heat shock, A375 melanoma cells exposed to serum starvation, growth factor deprived human endothelial cells). To our surprise, KYNA, at low concentration, inhibited FGF-1 release in all cellular models. QUIN, a compound having opposite effects on glutamate receptors, also reduced this release, but its potency was significantly lower than that of KYNA. KYNA and QUIN also displayed a major stimulatory effect on the proliferation rate of mouse microglia and human glioblastoma cells, in vitro. Our data suggest that minor changes of local KYNA concentration may modulate FGF-1 release, cell proliferation, and ultimately tissue damage in different pathological conditions.